

trix, and 2 signals acquired. After the IV administration of 0.1 mmol of gadopentetate dimeglumine (Magnevist, Schering) per kilogram of body weight, transverse T1-weighted images with ($n = 3$) or without ($n = 1$) fat suppression were obtained in the sagittal and coronal planes.

MR images were reviewed by two radiologists and findings were recorded by consensus. Images were evaluated for lesion location and size, depth (superficial or deep), shape of margin (well or ill defined), and the presence or absence of extracompartmental extension. To define depth, superficial lesions did not involve the superficial fascia, and deep lesions were deep in relation to or invaded the superficial fascia. The relationship between tumor and the underlying tendon sheath was also evaluated. MR images were evaluated for predominant signal intensity characteristics (low, intermediate, high), signal homogeneity or heterogeneity, and enhancement characteristics. On T1-weighted images, low signal intensity was defined as signal intensity less than that of muscle; intermediate signal intensity, similar to that of muscle; and high signal intensity, similar to that of fat. On T2-weighted images, low signal intensity was defined as signal intensity similar to that of muscle; intermediate signal intensity, greater than that of muscle but less than that of fat; and high signal intensity, equal to or greater than that of fat. Tumor enhancement was visually graded as greater than, less than, or equal to that of surrounding muscle and vessels.

Results

Clinical Features

All patients were symptomatic at presentation. Presenting complaints were painless swelling of the distal extremities. The mean symptom duration was 4.8 months. Tumors arose from the feet ($n = 2$), hands ($n = 1$), and fingers ($n = 1$). All patients received excisional biopsy for definitive diagnosis and primary therapy. Surgical margins were adequate in three patients and inadequate in one patient. The one patient with an inadequate surgical margin underwent subsequent wide resection. Chemotherapy and radiation therapy were not included in the treatment regimen in any patient. Local recurrence occurred 26.5 months after the initial surgery in two patients. These patients received wide resection. At the latest follow-up (27–82 months; mean, 45 months), no patients had developed further recurrence or metastasis.

MRI Findings and Pathologic Correlations

The gross characteristics of the resected specimens featured multinodular architecture corresponding to MRI features. The mean tumor diameter was 2.4 cm (range, 1.2–3.0 cm). Tumors were located along the tendon sheath in all patients. Findings of extensive involvement surrounding the tendon sheath by the tumor were

seen. In two patients, the tumor existed beneath the tendon sheath (Fig. 1), and in two it involved the surrounding tendon sheath diffusely and focally infiltrated the dermis (Fig. 2). One patient had an ill-defined, irregularly margined mass involving the ulnar nerve and the tendon sheath of the flexor carpi ulnaris (Fig. 2).

Cortical invasion was not identified in any patient on radiographs. All tumors showed predominantly low signal intensity relative to muscle on T1-weighted MR images (Fig. 3). Two lesions showed moderate and homogeneous enhancement after the IV administration of contrast material (Figs. 1 and 3). The cut surface of resected specimens showed solid nests of neoplastic cells that featured spindle and epithelioid cells with higher cellularity, which corresponded to homogeneous enhancement on contrast-enhanced MR images. Two lesions showed heterogeneous enhancement of the tumor that correlated with geographic areas of the myxoid stromal matrix on microscopic observations (Fig. 4). On T2-weighted MR images, all lesions had intermediate signal intensity greater than that of muscle but less than that of fat (Fig. 2). In all cases, the cut surface of specimens revealed solid nests of cellular areas with foci of hyalinized collagen fibers and hypocellular areas with a myxoid stromal




Fig. 1.—Myxoinflammatory fibroblastic sarcoma in 62-year-old man with painless mass in finger.
A, Sagittal T1-weighted MR image (TR/TE, 450/15) shows poorly circumscribed mass beneath tendon sheath of flexor hallucis longus (arrows).
B, Sagittal contrast-enhanced T1-weighted MR image (450/15) shows homogeneous enhancement (arrows).
C, Photograph of histopathologic specimen shows solid nests of spindle and epithelioid tumor cells with foci of inflammatory cell infiltrate (arrows).

MRI of Myxoinflammatory Fibroblastic Sarcoma

matrix, which corresponded to the imaging appearance of intermediate signal intensity on T2-weighted MR images.

Two patients developed recurrent tumors and underwent follow-up MRI after treatment. One patient developed a mass of sheetlike appearance beneath the dorsal portion of the underlying tendon sheath (Fig. 3). Signal characteristics and homogeneous enhancement patterns were similar to those of the primary tumors. Histopathologic examination of this patient showed an infiltrate of lymphoid cells and a marked proliferation of spindle-shaped tumor cells surrounding the tendon sheaths.

In the second patient, a mass of branching pattern occurred along the extensor digitorum

longus tendon sheaths of the second and fourth toes without distortion of the architecture of the tendon sheaths (Fig. 4). This patient had also MRI findings suggesting capsular involvement in the metatarsophalangeal joint of the second toe. Histopathologic examination revealed that the tumor arose from the extensor digitorum longus tendon sheaths and also involved the extensor digitorum brevis tendon sheath, cutaneous nerve, and dermis.

Discussion

Myxoinflammatory fibroblastic sarcoma is a rare tumor of the subcutaneous soft tissue that can arise on the trunk but most commonly occurs in the distant extremities [1, 2]. According to the lit-

erature and our experience, myxoinflammatory fibroblastic sarcoma is a tumor that most commonly affects adults who are symptomatic at presentation [1, 2]. All patients in our series were symptomatic, with common complaints of a painless mass.


Myxoinflammatory fibroblastic sarcoma has a relatively good prognosis with a long life expectancy despite frequent local recurrence [1–3]. Two of our patients developed local recurrence, with an average duration of 26.5 months. According to the literature, the local recurrence rate in patients with myxoinflammatory fibroblastic sarcoma ranges from 22% to 67% [1, 2]. The metastasis rate in patients with myxoinflammatory fibroblastic sarcoma is uncertain. Metastases have been reported to develop in only a few cases [1].

Fig. 2.—Myxoinflammatory fibroblastic sarcoma in 31-year-old man with painless mass in subcutaneous soft tissue of wrist.


A, Coronal contrast-enhanced T1-weighted MR image (TR/TE, 520/15) shows poorly circumscribed mass with ill-defined border. Tumor involves surrounding tendon sheath diffusely and focally infiltrates dermis (arrow).

B, Axial contrast-enhanced T1-weighted MR image (520/15) shows mass involving ulnar nerve (arrow) and tendon sheath of flexor carpi ulnaris (arrowhead).


C, Photograph of histopathologic specimen reveals that numerous small nodules consisting of tumor cells infiltrate along ulnar nerve (arrows).



A



B



C

In all of our patients, excisional biopsy for definitive diagnosis and primary therapy was performed. However, tumor margins in one of our patients were inadequate and the patient underwent subsequent wide resection. Tumors are often removed piecemeal by surgical procedures, with curative wide resection considered to be the adequate treatment of choice [1].

Grossly, myxoinflammatory fibroblastic sarcoma forms a poorly circumscribed mass surrounding the tendon sheath that may extend into the dermis and skeletal muscle. Microscopically, the tumor is characterized by solid nests of atypical spindle and epithelioid cells in a myxoid stroma and dense inflammatory infiltrates. The tu-


mor cells often have large vesicular nuclei similar to those of virocytes or Reed-Sternberg cells. The immunophenotype is positive for vimentin, with variable immunoreactivity for CD34, CD68, cytokeratin, and smooth-muscle actin [1-6].

On MR images, myxoinflammatory fibroblastic sarcoma typically manifests as a poorly circumscribed mass with a multinodular appearance. Extensive involvement surrounding the tendon sheath is also a common feature.

The appearance of the extension along the tendon sheath in this tumor is similar to that seen in tenosynovitis. Differentiating tenosynovitis from myxoinflammatory fibroblastic sarcoma solely on MRI findings is difficult. Tenosynovi-

tis also can lead to an ill-defined soft-tissue mass or enlargement of its sheath. However, this condition typically manifests as the accumulation of fluid with increased signal intensity of the affected tendon on T2-weighted MR images [8]. Clinical characteristics can allow the differentiation of tenosynovitis from myxoinflammatory fibroblastic sarcoma because tenosynovitis often decreases in size during the course of disease, whereas myxoinflammatory fibroblastic sarcoma usually grows with infiltration [1].


MRI findings of myxoinflammatory fibroblastic sarcoma also closely resemble those of giant cell tumors of the tendon sheath, proliferative fasciitis, acral fibromyxoma, myxoid



A



B



C

Fig. 3.—Myxoinflammatory fibroblastic sarcoma in foot of 32-year-old woman with local recurrence.

A, Sagittal T2-weighted MR image (TR/TE, 3,600/120) shows mass of sheetlike appearance beneath dorsal portion of tendon sheath. Tumor shows intermediate signal intensity, greater than that of muscle (arrow).

B, Sagittal contrast-enhanced fat-saturated T1-weighted MR image (520/15) shows homogeneous enhancement of tumor (arrows).

C, Photograph of histopathologic specimen shows sheetlike proliferation of spindle-shaped tumor cells (arrows) with ganglionlike cells, Reed-Sternberg-like cells, and lymphoid cells surrounding tendon sheaths.

MRI of Myxoinflammatory Fibroblastic Sarcoma




Fig. 4.—Myxoinflammatory fibroblastic sarcoma in foot of 24-year-old man with local recurrence.

A, Coronal fat-saturated T2-weighted MR image (TR/TE, 3,500/105) shows mass of branching pattern that occurred along extensor digitorum longus tendon sheaths of second and fourth toes (arrows). Tumor shows intermediate signal intensity, greater than that of muscle.

B, Coronal contrast-enhanced T1-weighted MR image (520/15) shows heterogeneous enhancement of tumor (arrows).

C, Photograph of histopathologic specimens shows proliferation of spindle-shaped tumor cells (arrows) with prominent nucleoli in abundant myxoid stromal matrix.

liposarcoma, and myxofibrosarcoma [9–13]. These conditions could not be distinguished radiologically from myxoinflammatory fibroblastic sarcoma on the basis of our study results. Signal characteristics and enhancement patterns were nonspecific. However, heterogeneous enhancement on contrast-enhanced MR images corresponded to geographic areas of the myxoid stromal matrix in the pathologic specimens. In two of our patients, MRI findings of recurrent tumors were ill defined and the tumors had sheetlike appearances involving the tendon sheath. A significant association may exist between recurrent tumors and the tendon sheath.

In summary, myxoinflammatory fibroblastic sarcoma typically affects adult subjects as a painless mass of the distal extremities at presentation. Myxoinflammatory fibroblastic sarcoma usually manifests on MR images as a multinodular and poorly circumscribed mass involving the surrounding tendon sheath. Although it is unlikely that such a rare condition could reasonably be diagnosed on the basis of MRI findings alone, the condition should be considered in the

differential diagnosis of a soft-tissue mass in the distal extremities of adult patients.

References

1. Meis-Kindblom JM, Kindblom LG. Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. *Am J Surg Pathol* 1998;22:911–924
2. Montgomery EA, Devaney KO, Giordano TJ, Weiss SW. Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin's disease, and various sarcomas. *Mod Pathol* 1998;11:384–391
3. Lambert I, Debiec-Rychter M, Guelinckx P, Hagemijer A, Sciort R. Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes. *Virchows Arch* 2001;438:509–512
4. Jurcic V, Zidar A, Montiel MD, et al. Myxoinflammatory fibroblastic sarcoma: a tumor not restricted to acral sites. *Ann Diagn Pathol* 2002;6:272–280
5. Sakaki M, Hirokawa M, Wakatsuki S, et al. Acral myxoinflammatory fibroblastic sarcoma: a report of five cases and review of the literature. *Virchows Arch* 2003;442:25–30
6. Pohar-Marinek Z, Flezar M, Lamovec J. Acral myxoinflammatory fibroblastic sarcoma in FNAB samples: can we distinguish it from other myxoid lesions? *Cytopathology* 2003;14:73–78
7. Weiss SW, Goldblum JR. *Enzinger and Weiss's soft tissue tumors*, 4th ed. St. Louis, MO: Mosby, 2001:1552–1571
8. Mallefert JF, Dardel P, Cherasse A, Mistrih R, Krause D, Tavernier C. Magnetic resonance imaging in the assessment of synovial inflammation of the hindfoot in patients with rheumatoid arthritis and other polyarthritis. *Eur J Radiol* 2003;47:1–5
9. Llauger J, Palmer J, Monill JM, Franquet T, Bague S, Roson N. MR imaging of benign soft-tissue masses of the foot and ankle. *RadioGraphics* 1998;18:1481–1498
10. Kato K, Ehara S, Nishida J, Satoh T. Rapid involution of proliferative fasciitis. *Skeletal Radiol* 2004;33:300–302
11. Fetsch JF, Laskin WB, Miettinen M. Superficial acral fibromyxoma: a clinicopathologic and immunohistochemical analysis of 37 cases of a distinctive soft tissue tumor with a predilection for the fingers and toes. *Hum Pathol* 2001;32:704–714
12. Tateishi U, Hasegawa T, Beppu Y, Kawai A, Satake M, Moriyama N. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. *AJR* 2004;182:725–731
13. Munk PL, Sallomi DF, Janzen DL, et al. Malignant fibrous histiocytoma of soft tissue imaging with emphasis on MRI. *J Comput Assist Tomogr* 1998;22:819–826

CHEST[®]

Official publication of the American College of Chest Physicians



Prediction of Lung Adenocarcinoma Without Vessel Invasion: A CT Scan Volumetric Analysis

Ukhide Tateishi, Hajime Uno, Kan Yonemori, Mistuo Satake, Masahiro Takeuchi and Yasuaki Arai

Chest 2005;128;3276-3283
DOI 10.1378/chest.128.5.3276

The online version of this article, along with updated information and services can be found online on the World Wide Web at:
<http://chestjournals.org/cgi/content/abstract/128/5/3276>

CHEST is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright 2007 by the American College of Chest Physicians, 3300 Dundee Road, Northbrook IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder (<http://www.chestjournal.org/misc/reprints.shtml>). ISSN: 0012-3692.

A M E R I C A N C O L L E G E O F



P H Y S I C I A N S[®]

Prediction of Lung Adenocarcinoma Without Vessel Invasion*

A CT Scan Volumetric Analysis

Ukihide Tateishi, MD, PhD; Hajime Uno, PhD; Kan Yonemori, MD; Mistuo Satake, MD; Masahiro Takeuchi, ScD, MPH; and Yasuaki Arai, MD, PhD

Study objectives: Patients with lung adenocarcinoma without vessel invasion have a favorable prognosis after resection and are among the candidates for limited surgery. The purpose of the present study was to predict lung adenocarcinoma without vessel invasion based on a volumetric analysis of the lesion with a CT scan prior to the operation.

Methods: CT scan images were obtained in 288 consecutive patients with adenocarcinoma of the lung before surgical resection. Total tumor volume, the volume of the nonsolid component, and the proportion occupied by the nonsolid component were calculated by the perimeter method. The performance of the derived logistic regression model and the volumetric results were evaluated by receiver operating characteristic analysis. The model derived for the prediction of tumors without vessel invasion was assessed by means of the leave-one-out cross-validation technique.

Results: The pathologic diagnosis was adenocarcinoma with vessel invasion in 160 cases, and without vessel invasion in 128 cases. The median total tumor volume, the median volume of the nonsolid component, and median proportion occupied by the nonsolid component were 1,123.7 mm³, 253.4 mm³, and 58.0%, respectively. With the derivation of the predictive rule, stepwise regression yielded the following five features: the proportion occupied by the nonsolid component; spiculation; pleural indentation; gender; and tumor size. The Az value, a measure of diagnostic power represented as the area under the curve, was 0.957 for prediction of lung adenocarcinoma without vessel invasion. The cross-validation accuracy achieved by applying the rule was 90.3%.

Conclusions: The proportion occupied by the nonsolid component based on a CT scan volumetric analysis was a reliable predictor of tumors without vessel invasion in patients with adenocarcinoma of the lung.
(CHEST 2005; 128:3276–3283)

Key words: CT scan; lung; lung cancer

Abbreviations: CI = confidence interval; OR = odds ratio; ROC = receiver operating characteristic; SPN = solitary pulmonary nodule

Patients with lung adenocarcinoma without vessel invasion clearly have the best outcome after resection, and they are among the candidates for

limited surgery.^{1,2} Some studies^{3,4} have highlighted the potential diagnostic role of thin-section CT scanning in identifying nonsolid components of adenocarcinoma of the lung. The nonsolid component is larger in patients with noninvasive tumors and has been shown to discriminate between patients with noninvasive tumors and patients with advanced tumors with a high degree of power.⁵ In addition, the proportion of the tumor occupied by the nonsolid component correlates well with the absence of vascular or lymphatic invasion and with better outcome.^{6–10} Thus, identification of the size of the nonsolid component on CT scan images of lung adenocarcinoma is a potential surrogate measurement for tumor aggressiveness.

The reliability of almost all data on the proportion

*From the Division of Diagnostic Radiology (Drs. Tateishi, Yonemori, Satake, and Arai), National Cancer Center Hospital, Tokyo, Japan; the Department of Biostatistics (Dr. Uno), Harvard School of Public Health, Boston, MA; and the Division of Biostatistics (Takeuchi), Kitasato University Graduate School, Tokyo, Japan.

Dr. Uno received support for this research by Banyu Life Science Foundation International.

Manuscript received January 12, 2005; revision accepted May 4, 2005.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

Correspondence to: Ukihide Tateishi, MD, PhD, Division of Diagnostic Radiology, National Cancer Center Hospital, Tsukiji, Chuo-Ku, 104-0045, Tokyo, Japan; e-mail: utateish@ncc.go.jp

occupied by the nonsolid component is limited, because the investigators assumed that the lesions were spherical and used the maximum cross-sectional diameter on CT scan images to calculate it,^{5,6} and the only large series to date used the maximum cross-sectional area of the tumor to predict invasion.¹¹ To our knowledge, few studies have used CT scanning to calculate the volume of the nonsolid component within tumors and to correlate the proportion occupied by the nonsolid component with pathologic characteristics of tumor invasion. Moreover, most studies to date have proposed diagnostic criteria for lesions without testing their diagnostic validity.⁶⁻¹¹

We therefore conducted both a derivation and validation cohort study of patients with adenocarcinoma of the lung in order to predict tumors without vessel invasion. Our results will assist physicians in estimating more accurately the probability of a tumor being unassociated with vessel invasion and to decide whether further investigation is necessary to rule the presence of a noninvasive tumor in or out.

MATERIALS AND METHODS

A retrospective review of the pathologic records for the period between October 2001 and January 2004 identified 288 who had been patients treated for adenocarcinoma of the lung the maximum dimension of which was < 2 cm. A consecutive subset of 288 patients contributed to the derivation analysis and the cross-validation analysis based on the leave-one-out method. The study population consisted of 113 men and 175 women, and their mean age was 64.7 years (age range, 41 to 86 years). All patients had undergone surgical resection consisting of wedge resection or lobectomy. Complete dissection ($n = 96$; 33%) and sampling of mediastinal or hilar lymph nodes ($n = 192$; 67%) were performed. The nodes included high and low ipsilateral, paratracheal, subcarinal, and inferior pulmonary ligament lymph nodes, and any other suspicious lymph nodes identified at surgery. Surgical specimens were fixed in formalin and embedded in paraffin. Four-micrometer sections were stained with hematoxylin and eosin and elastica-van Gieson stain. Tumors without vessel invasion were diagnosed when no lymphatic or blood vessel invasion was identified within the lesion microscopically. Based on the current international TNM classification for staging lung cancer,¹² 274 tumors (95%) were classified as stage Ia, and the other 14 tumors (5%) were classified as stage IIa. The clinical records of all patients were available for review. No patients were lost to follow-up, which began on the date of the initial operation. The median duration of follow-up was 22 months, and ranged from 1 to 40 months. This study was approved by our institutional review board after confirmation of informed consent by the patients to a review of their records and images.

CT scanning was performed with a multidetector scanner (Aquilion V-detector; Toshiba Medical Systems; Tokyo, Japan) by using axial 2.0-mm \times 4 or 1.0-mm \times 16 modes (ie, 4 or 16 images per gantry rotation), 120 kVp, 200 to 250 mA, and a 0.5-s scanning time. Thin-section CT scan images were obtained using 2.0-mm sections that were reconstructed at 2.0-mm intervals by means of a high-spatial frequency algorithm and were retrospectively retargeted to each lung with a 20-cm field of view. All

images were displayed at window settings for lung (center, -600 Hounsfield units; width, 2,000 Hounsfield units). Image viewing and manipulation were controlled with a workstation (ZIOSOFT M900, Quadra, version 3.10f; ZIOSoft Inc; Tokyo, Japan) that allows the reader to draw lines through regions of interest and the perimeters around them.

The CT scan images were assessed in random order by two independent observers without reference to the clinical findings. The observers examined the images for the following: maximum tumor diameter; nodular edge (irregular or not); presence of a nonsolid component; presence of an air-bronchogram; presence of cavitation, lobulation, pleural indentation, bubble-like lucencies, spiculation, vascular convergence, bronchiectasis, or bronchiolectasis; and the lobe in which the lesion was located (eg, upper, middle, or lower). *Nonsolid component* was defined as an area of ground-glass attenuation or hazy increased parenchymal attenuation without obscuring of the underlying vascular markings. We distinguished between *nonsolid tumors* and *part-solid tumors*, with the former being defined as tumors containing only a nonsolid component, and the latter as tumors that contained a partially solid component. Bubble-like lucencies were diagnosed when there were multiple cystic air spaces measuring ≤ 5 mm in diameter within the lesion surrounded by a wall of variable thickness.¹³ After an initial independent evaluation, the two observers reviewed all cases in which their interpretations disagreed and reached a final decision by consensus.

The volume of each tumor was calculated by the perimeter method.¹⁴⁻¹⁶ The cross-sectional areas of the entire tumor and of the solid component were calculated by a workstation that manipulates a voxel matrix of 512×512 pixels. Two board-certified radiologists who were experienced with image-viewing and image-manipulation software drew a line around the perimeter of each tumor twice. The total tumor volume and the volume of the solid component were calculated by summing the cross-sectional areas and multiplying by the section increment. The volume of the nonsolid component was calculated by subtracting the volume of the solid component from the total volume. The averages of the two volume values calculated by each of the two observers were used in the analyses.

Statistical Analysis

Interobserver variation in relation to CT scan findings was quantified as the weighted κ coefficient of agreement. The predictive performance of volumetric data was evaluated by receiver operating characteristic (ROC) analysis, and the areas under curve were represented by the Az values, which are a measure of diagnostic power represented by the area under the curve.^{17,18} A stepwise procedure was used in the logistic regression analysis to select the independent variables that should have been included in the model to predict tumors without vessel invasion. A variable was entered into the model if the probability of its score statistic was < 0.05 . The odds ratio (OR) and 95% confidence interval (CI) for the multivariate predictors were estimated. The Hosmer-Lemeshow test was also performed to evaluate goodness-of-fit.¹⁹ Calibration curves comparing the observed proportion of tumors without vessel invasion with the probability of tumors without vessel invasion ordered by the increasing probability of tumors without vessel invasion were constructed. The performance of the learned model was verified by using the leave-one-out cross-validation method, in which all cases but one were used to train the prediction rule, which was then applied to the single excluded case.²⁰⁻²² This procedure was repeated for each case, until each case had been left out only once. Cross-validation accuracy was calculated by comparing the predicted response and the observed response.²³ The following variables were considered for their prognostic value: age; gender;

Table 1—Patient Demographics*

Characteristics	No Vessel Invasion (n = 128)	Vessel Invasion (n = 160)
Gender		
Male	39 (30)	74 (46)
Female	89 (70)	86 (54)
Age,† yr		
Mean	64	65.4
SD	9.1	8.8
Range	41–84	41–86
Location of tumor		
Upper lobe	78 (61)	91 (57)
Middle lobe	14 (11)	5 (3)
Lower lobe	36 (28)	64 (40)
Tumor size,‡ mm		
Mean	12.4	15.8
SD	4.5	3.5
Range	5.0–20.0	7.0–20.0
Tumor with nonsolid component	124 (97)	78 (49)
Nonsolid tumor	81 (63)	1 (1)
Part-solid tumor	43 (34)	77 (48)
Solid tumor	4 (3)	82 (51)

*Values are given as No. (%).

†The differences between two groups were assessed by a two-sample *t* test. The two tumor subgroups differed significantly in terms of gender (p 0.01 [χ^2 test]). Tumors without vessel invasion were significantly more frequent (p 0.01 [χ^2 test]) in the upper lobe than those with vessel invasion. Tumor size was significantly smaller in tumors without vessel invasion (p 0.01 [*t* test]) than that in tumors with vessel invasion. Tumors with a nonsolid component were significantly more frequent (p 0.0001 [χ^2 test]) among tumors without vessel invasion.

presence or absence of vessel invasion; tumor size; total tumor volume; the volume of the nonsolid component; the proportion occupied by the nonsolid component; and CT scan findings. Univariate analysis was performed by comparing Kaplan-Meier disease-free or recurrence-free survival curves and carrying out log-rank tests. All analyses were conducted using a statistical

software package (SAS, version 8.2; SAS Institute, Cary, NC; and R software, version 1.9.0; R project, Center for Computational Intelligence; Vienna, Austria).

RESULTS

The clinical characteristics and outcomes of all patients with adenocarcinoma of the lung are summarized in Table 1. The pathologic diagnosis was lung adenocarcinoma with vessel invasion in 160 of the 288 patients (55.6%), and without vessel invasion in the other 128 patients (44.4%). Female patients had a predilection for tumors without vessel invasion according to the results of the univariate analysis. The median age at presentation was 66 years (age range, 41 to 86 years). Age was not statistically associated with tumor type. Most tumors (n = 169; 58.7%) were in the upper lobe. The median tumor size was 15.0 mm (range, 5.0 to 20.0 mm). Tumors with vessel invasion were significantly larger than tumors without vessel invasion. Among the tumors without vessel invasion, nonsolid tumors (n = 81; 28.1%) were more common than part-solid or solid tumors (n = 47; 16.3%); whereas, among the tumors with vessel invasion, solid or part-solid tumors (n = 159; 55.2%) were more common than nonsolid tumors (n = 1; 0.3%). Tumors with a nonsolid component were more common among the tumors without vessel invasion than among the tumors with vessel invasion.

There was good interobserver agreement in the analysis of the CT scan findings (weighted κ coefficient, 0.63 to 0.79). The following CT scan findings were more frequently identified in tumors with vessel invasion than in tumors without vessel invasion according to the univariate analysis: cavitation; air bronchogram;

Table 2—Summary Statistics of Volumetric Measurements*

Variables	No Vessel Invasion	Vessel Invasion
Tumor volume, mm ³		
Mean	1,155.7	1,773.6
SD	1,411.1	1,321.3
Q1-Median-Q3	247.6–713.8–1,544.6	867.1–1,492.5–2,367.4
Range	43.6–6,828.0	120.8–6,912.2
Volume of nonsolid component, mm ³		
Mean	1,027.5	496.9
SD	1,372.7	829.6
Q1-Median-Q3	157.5–567.7–1,413.3	0.0–0.0–658.5
Range	0.0–6,593.4	0.0–4583.6
Proportion of nonsolid component, %		
Mean	88.1	24.3
SD	26.4	33.2
Q1-Median-Q3	93.4–100.0–100.0	0.0–0.0–41.4
Range	0.0–100.0	0.0–100.0

*The differences between two groups were assessed by the Wilcoxon two-sample *t* test. The tumor subgroups differed significantly in terms of the volume of those three kinds of measurements (p 0.0001). Q1 = 25th percentile; Q3 = 75th percentile.




FIGURE 1. Top, A: ROC curve for total tumor volume determined by the perimeter method. The mean (\pm SE) Az value was 0.699 ± 0.030 . Middle, B: the ROC curve for the volume of the nonsolid component determined by the perimeter method. The mean Az (\pm SE) value was 0.714 ± 0.030 . Bottom, C: ROC curve for the proportion occupied by the nonsolid component determined by the perimeter method. The mean Az (\pm SE) value was 0.928 ± 0.015 .

irregular margin; speculation; lobulation; and bronchiectasis or bronchiolectasis. Irregular margins were common in tumors without vessel invasion but were more frequent in tumors with vessel invasion. Vascular convergence was a less common finding and was noted only in patients with tumors that were associated with vessel invasion. Bubble-like lucencies were observed in one tumor with vessel invasion and in one tumor without vessel invasion.

Volumetric Analysis

The results of the volumetric analysis are summarized in Table 2. The median total tumor volume, the median volume of the nonsolid component, and the median proportion occupied by the nonsolid component were $1,123.7 \text{ mm}^3$ (range, 43.6 to $6,912.2 \text{ mm}^3$),

253.4 mm^3 (range, 0 to $6,593.4 \text{ mm}^3$), and 58.0% (range, 0 to 100%), respectively. Significant differences were found between the mean values for total volume and the proportion values in two groups. The ROC analyses to predict tumors without vessel invasion revealed that Az values of total tumor volume, the volume of the nonsolid component, and the proportion occupied by the nonsolid component were 0.699 (95% CI, 0.638 to 0.760), 0.714 (95% CI, 0.653 to 0.775), and 0.928 (95% CI, 0.895 to 0.961), respectively (Fig 1). The potential predictors of tumors without vessel invasion at the threshold of each median value were as follows: total tumor volume; the volume of the nonsolid component; and the proportion occupied by the nonsolid component (Table 3). Univariate analysis showed that our pre-

Table 3—Potential Predictors of Tumors Without Vessel Invasion*

Criteria	Proportion of Tumors Without Vessel Invasion, %	OR	95% CI	p Value†
Gender		1.9636	1.2053–3.1992	0.0064
Female	50.9			
Male	34.5			
Age		1.1124	0.6983–1.7723	0.6543
≤ 66 yr	45.7			
> 66 yr	43.1			
Tumor size		4.0588	2.4416–6.7472	< 0.0001
≤ 15 mm	58.5			
> 15 mm	25.8			
Air bronchogram		0.1143	0.0585–0.2235	< 0.0001
Positive	13.6			
Negative	58.0			
Irregular margin		0.1605	0.0636–0.4049	< 0.0001
Positive	40.1			
Negative	80.6			
Spiculation		0.0349	0.0159–0.0767	< 0.0001
Positive	7.1			
Negative	68.6			
Lobulation		0.1496	0.0185–1.2122	0.0412
Positive	11.1			
Negative	45.5			
Pleural indentation		0.1148	0.0673–0.1961	< 0.0001
Positive	21.2			
Negative	70.1			
Bubble-like lucencies		1.2540	0.1742–9.0269	0.8221
Positive	50.0			
Negative	44.4			
Vascular convergence		NA	NA	< 0.0001
Positive	0.0			
Negative	50.0			
Bronchiectasis or bronchiolectasis		0.2150	0.0468–0.9882	0.0312
Positive	15.4			
Negative	45			
Tumor volume		2.9934	1.8465–4.8528	< 0.0001
≤ 1,123.7 mm ³	57.6			
> 1,123.7 mm ³	31.3			
Volume of nonsolid component		2.6535	1.6431–4.2853	< 0.0001
> 253.4 mm ³	56.3			
≤ 253.4 mm ³	32.6			
Proportion of nonsolid component		42.778	21.5856–84.7761	< 0.0001
> 80%	84.6			
≤ 80%	11.4			

*The median value was considered to be a cutoff in age, tumor size, tumor volume, the volume of the nonsolid component, and the proportion of the nonsolid component. NA = not applicable.

† χ^2 test.

dicator of interest, the proportion occupied by the nonsolid component, was highly predictive of tumors without vessel invasion at an OR of 42.8 (95% CI, 21.6 to 84.8) with 80.0% as the threshold value.

Derivation of the Prediction Rule

From the 13 variables that reached the level of statistical significance in the univariate analyses comparing tumors with and without vessel invasion, we excluded location of the tumor because the absolute difference fell within the precision range of the test.

The logistic regression analysis identified the following five significant predictors of tumors without vessel invasion: proportion occupied by the nonsolid component; spiculation; pleural indentation; gender; and tumor size (Table 4). The Az value of the ROC analysis for prediction of a tumor without vessel invasion in the derivation phase was 0.957 (Fig 2). We adopted the threshold that yielded an appropriate tradeoff between sensitivity and specificity (*ie*, probability of a tumor without vessel invasion, 0.5). At that point in the ROC curve, the sensitivity, specificity, accuracy, positive predictive value, and

Table 4—Significant Predictors of Tumors Without Vessel Invasion

Variables	Coefficient	OR*	95% CI	p Value
Intercept	-1.6729			
Proportion of nonsolid component > 80% vs ≤ 80%	3.5744	35.673	14.392–88.421	< 0.0001
Positive vs negative spiculation	-2.3889	0.092	0.032–0.261	< 0.0001
Positive vs negative pleural indentation	-1.3982	0.247	0.101–0.602	0.0021
Female vs male gender	1.0056	2.734	1.141–6.551	0.0241
Tumor size ≤ 15 mm vs > 15.0 mm	1.1271	3.087	1.249–7.627	0.0146

*OR was presented to predict tumors without vessel invasion.

negative predictive value of the rule were 88.3%, 91.9%, 90.3%, 89.7%, and 90.7%, respectively. The results of the goodness-of-fit test (χ^2 , 3.6563; degrees of freedom, 8; $p = 0.89$) indicated that the observed proportion of patients with tumors without vessel invasion was similar to the predicted proportion in the derivation group. The calibration curves for the derivation data demonstrated good calibration of the prediction rule.

Cross-Validation Accuracy

When the rule derived from the 288 patients was applied to the leave-one-out cross-validation cohort, the validation accuracy based on the leave-one-out method was 90.3%, which was quite similar to the model accuracy, suggesting that the rule that was derived to predict tumors without vessel invasion is stable.




FIGURE 2. ROC curve for the derived model to predict tumor without vessel invasion. The probability of the occurrence of a tumor without vessel invasion based on the derived model can be considered diagnostic, and the tradeoff between sensitivity and specificity at various thresholds of the probability of a tumor without vessel invasion is given by the ROC curve.

Prognostic Analysis

At the last follow-up, 1 of the 288 patients (0.3%) had died, 12 patients (4.2%) were alive with recurrent disease, and the 5-year overall survival rate was 98.7%. Univariate analysis revealed that none of the variables had a significant impact on overall survival. The 5-year recurrence-free survival rate was 83.5%. The patients with tumors without vessel involvement had a 5-year recurrence-free rate of 88.0%, which was significantly better than the rate of 74.6% among the patients with vessel invasion ($p < 0.05$). Cavitation and vascular convergence were significantly associated with recurrence-free survival according to the univariate analysis ($p < 0.01$).

DISCUSSION

The proportion occupied by the nonsolid component is characteristically higher in patients with lung adenocarcinoma without vessel invasion, and several studies^{4,5} have demonstrated that it distinguishes tumors without vessel invasion from tumors with vessel invasion. Nevertheless, controversy remains regarding its reproducibility in optimally distinguishing tumors without vessel invasion from tumors with vessel invasion. In this study, we investigated the diagnostic capacity of the proportion occupied by the nonsolid component to predict tumors without vessel invasion in a well-characterized study population.

We performed ROC analysis to assess the ability of the proportion occupied by the nonsolid component to discriminate between tumors with and without vessel invasion. We have documented that the diagnostic probability of the proportion occupied by the nonsolid component for tumors without vessel invasion is accurate. The Az value observed for the proportion occupied by the nonsolid component was 0.957. In our study population, its discriminatory capacity yielded positive and negative predictive values for tumors without vessel invasion of 89.7% and 90.7%, respectively. These observations suggest that the identification of the proportion occupied by the nonsolid component on CT images may be useful

for predicting tumors without vessel invasion in patients with adenocarcinoma of the lung.

At both baseline screenings and repeat CT screenings for lung cancer, tumors containing a nonsolid component have been found to be a significant sign of malignancy.²⁴ Henschke and colleagues²⁵ found that 19% of the 233 cases with positive results at baseline screening had a tumor with the nonsolid component and that the tumors were predominantly bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar carcinoma features. These predominant histologic types of malignancy corresponded to noninvasive and invasive tumors of lung adenocarcinoma. The quantification of the extent or growth rate of the solid and nonsolid components of tumors is necessary during CT scan screening for lung cancer.

Swensen and colleagues¹⁸ created a multivariate logistic regression model to predict a malignant solitary pulmonary nodule (SPN) in a derivation and validation analysis. Of 629 radiologically intermediate nodules in their study, 23% were malignant SPNs. The investigators identified the following three independent findings that predicted malignant SPNs: upper lobe distribution; tumor size; and spiculation. Among these findings, spiculation was associated with the prediction model in our results. Pleural indentation and male predilection were also significant predictors of tumors with vessel invasion in our study.

Some studies^{26–28} using the segmentation algorithm of software have yielded calculations of tumor volume in three dimensions. The excellent interobserver variability suggests that tumor volume estimations by different observers can be reliably compared when three-dimensional volumetric software is used. However, this technique does not enable the segmentation of tumors that contain a nonsolid component.^{27,28} Since most tumors in our study contained a nonsolid component and were not appropriate for three-dimensional volumetric analysis, tumor volume was calculated by the perimeter method, which had potential sources of error that affected the results of volumetric analyses.²⁹

The proportion occupied by the nonsolid component was dichotomized using the median value for a threshold level in the univariate and multivariate analyses performed. In both the univariate and multivariate analyses, the proportion occupied by the nonsolid component yielded the highest point estimates and CIs for the ORs of tumors without vessel invasion. However, it should be noted that there was enough of a difference between the values for patients in whom the nonsolid component occupied a high proportion of the tumor and those for patients in whom the nonsolid component occupied a small

proportion of the tumor that similar results could have been obtained with different threshold values.

There are other potential limitations of this study. The size of the sample may also have led to false-positive results because of the number of covariates included in the initial analysis. However, the strength of the association with our primary outcome of interest, as well as the historical precedence of other significant predictors in our multivariate analysis, lends credence to our conclusions. In summary, the results of our study confirm that the proportion occupied by the nonsolid component of a tumor on CT scans is a reliable predictor of tumors without vessel invasion with much greater confidence than was possible in the past.

REFERENCES

- 1 Travis WD, Colby TV, Corrin B, et al. Histological typing of lung and pleural tumors. Berlin, Germany: Springer, 1999
- 2 Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. *Cancer* 1995; 75:2844–2852
- 3 Jang HJ, Lee KS, Kwon OJ, et al. Bronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign. *Radiology* 1996; 199:485–488
- 4 Kuriyama K, Seto M, Kasugai T, et al. Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung. *AJR Am J Roentgenol* 1999; 173:465–469
- 5 Ohde Y, Nagai K, Yoshida J, et al. The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma. *Lung Cancer* 2003; 42: 303–310
- 6 Aoki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. *Radiology* 2001; 220:803–809
- 7 Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. *Ann Thorac Surg* 2000; 69:893–897
- 8 Kodama K, Higashiyama M, Yokouchi H, et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. *Lung Cancer* 2002; 33:17–25
- 9 Matsunaga H, Yokoi K, Anraku M, et al. Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1N0M0 adenocarcinoma of the lung: a predictor of lymph node metastasis. *J Thorac Cardiovasc Surg* 2002; 124:278–284
- 10 Kim EA, Johkoh T, Lee KS, et al. Quantification of ground-glass opacity on high-resolution CT of small peripheral adenocarcinoma of the lung: pathologic and prognostic implications. *AJR Am J Roentgenol* 2001; 177:1417–1422
- 11 Takashima S, Maruyama Y, Hasegawa M, et al. Prognostic significance of high-resolution CT findings in small peripheral adenocarcinoma of the lung: a retrospective study on 64 patients. *Lung Cancer* 2002; 36:289–295
- 12 Lababede O, Meziane MA, Rice TW. TNM staging of lung cancer: a quick reference chart. *Chest* 1999; 115:233–235
- 13 Adler B, Padley S, Miller RR, et al. High-resolution CT of bronchioloalveolar carcinoma. *AJR Am J Roentgenol* 1992; 159:275–277

- 14 Winter-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. *Radiology* 2002; 223:798–805
- 15 Winter-Muram HT, Jennings SG, Meyer CA, et al. Effect of varying CT section width on volumetric measurement of lung tumors and application of compensatory equations. *Radiology* 2003; 229:184–194
- 16 Jennings SG, Winter-Muram HT, Tarver RD, et al. Lung tumor growth: assessment with CT-comparison of diameter and cross-sectional area with volume measurements. *Radiology* 2004; 231:866–871
- 17 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982; 143:29–36
- 18 Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules: application to small radiologically intermediate nodules. *Arch Intern Med* 1997; 157:849–855
- 19 Lemeshow S, Hosmer DW. A review of goodness-of-fit statistics for use in the development of logistic regression models. *Am J Epidemiol* 1982; 115:92–106
- 20 Wasson JH, Sox HC, Neff RK, et al. Clinical prediction rules: applications and methodological standards. *N Engl J Med* 1985; 313:793–799
- 21 Scott JA. Pulmonary perfusion patterns and pulmonary arterial pressure. *Radiology* 2002; 224:513–518
- 22 Arana E, Delicado P, Marti-Bormati L. Validation procedures in radiologic diagnostic models: neural network and logistic regression. *Invest Radiol* 1999; 34:636–642
- 23 Stone M. Cross-validatory choice and assessment of statistical predictions. *J R Stat Soc B* 1974; 36:111–147
- 24 Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: overall design and findings from baseline screening. *Lancet* 1999; 354:99–105
- 25 Henschke CI, Yankelevitz DF, Mircheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. *AJR Am J Roentgenol* 2002; 178:1053–1057
- 26 Yankelevitz DF, Reeves AP, Kostis WJ, et al. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. *Radiology* 2000; 217:251–256
- 27 Revel MP, Lefort C, Bissery A, et al. Pulmonary nodules: preliminary experience with three-dimensional evaluation. *Radiology* 2004; 231:459–466
- 28 Revel MP, Bissery A, Bienvenu M, et al. Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? *Radiology* 2004; 231:453–458
- 29 Staron RB, Ford E. Computed tomographic volumetric calcification reproducibility. *Invest Radiol* 1986; 21:272–274

Prediction of Lung Adenocarcinoma Without Vessel Invasion: A CT Scan Volumetric Analysis

Ukihide Tateishi, Hajime Uno, Kan Yonemori, Mistuo Satake, Masahiro Takeuchi and Yasuaki Arai

Chest 2005;128;3276-3283
DOI 10.1378/chest.128.5.3276

This information is current as of February 25, 2007

Updated Information & Services	Updated information and services, including high-resolution figures, can be found at: http://chestjournals.org/cgi/content/full/128/5/3276
References	This article cites 25 articles, 19 of which you can access for free at: http://chestjournals.org/cgi/content/full/128/5/3276#BIBL
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://chestjournals.org/misc/reprints.shtml
Reprints	Information about ordering reprints can be found online: http://chestjournals.org/misc/reprints.shtml
Email alerting service	Receive free email alerts when new articles cite this article sign up in the box at the top right corner of the online article.
Images in PowerPoint format	Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online article figure for directions.

A M E R I C A N C O L L E G E O F



P H Y S I C I A N S[®]

Incidence of Multiple Primary Malignancies in a Cohort of Adult Patients with Soft Tissue Sarcoma

Ukihide Tateishi¹, Tadashi Hasegawa², Seiichiro Yamamoto³, Umio Yamaguchi⁴, Ryohei Yokoyama⁵, Hiroshi Kawamoto³, Mitsuo Satake¹ and Yasuaki Arai¹

¹Diagnostic Radiology Division, ²Pathology Division and ⁴Orthopedic Surgery Division, National Cancer Center Hospital and Institute, ³Statistics and Cancer Control Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo and ⁵Department of Orthopedic Surgery, Kyushu Cancer Center, Fukuoka, Japan

Received March 6, 2005; accepted June 1, 2005; published online July 15, 2005

Objective: Some studies to date have suggested the development of multiple primary malignancies in patients with soft tissue sarcoma. The current study was performed to quantify the risk of development of multiple primary malignancies in adult patients with soft tissue sarcoma.

Methods: A total of 406 consecutive patients who were diagnosed with soft tissue sarcoma were identified in the study analysis. The cumulative incidence of multiple malignancies was calculated by comparing Kaplan–Meier curves and log-rank tests from each histological type. A Cox proportional hazards model was used to estimate the influence on the hazard ratio (HR) of each variable.

Results: A total of 35 patients with soft tissue sarcoma (9%), having preceding ($n = 15$) and subsequent ($n = 20$) malignancies other than soft tissue sarcoma were documented. The 5- and 10-year estimated cumulative incidence of multiple primary malignancies were 7.6 and 12.3%, respectively. The hazard risk of multiple primary malignancies adjusted for potential confounding variables was significantly associated with age at diagnosis ($HR = 1.51$, $P = 0.0019$). The risk of multiple primary malignancies was also increased in patients with myxofibrosarcoma adjusted by the potential confounding variables ($HR = 2.34$, $P = 0.048$). The 5- and 10-year estimated cumulative incidence of multiple primary malignancies in patients with myxofibrosarcoma were both 16.9%.

Conclusion: The results of our study confirm that the risk of multiple malignancies appears to be impacted by age at the time of diagnosis of the first tumor and by the histological type of myxofibrosarcoma.

Key words: soft tissue sarcoma – myxofibrosarcoma – multiple malignancies – second primary tumor

INTRODUCTION

The development of multiple malignancies in a single individual has been reported after successful treatment of primary tumors (1,2). The greatest attention has been focused on second primary tumors (SPTs) after treatment of malignant lymphoma (3), retinoblastoma (4) and malignant germ cell tumor (5,6) because good cure rates have been achieved for many years, resulting in many long-term survivors.

The occurrence of multiple malignancies in patients with soft tissue sarcoma (STS) has also been reported (7,8). Studies focused on patients with osteosarcoma have revealed an overall 10-year cumulative incidence of SPT of 2.0–3.1% (9,10). Adult patients with STS have been found to develop other malignant neoplasms either before or after the diagnosis of

STS, and this phenomenon occurred at a significantly higher rate than reported for the occurrence of STS in the general cancer population (11).

However, the risk of SPT after treatment of the first tumor has been mainly described in children with STS. Although we have observed the occurrence of multiple primary malignancies that occurred in adult patients with various histological types of STS, especially pleomorphic malignant fibrous histiocytoma (MFH) and myxofibrosarcoma, in daily clinical practice there has been little information on the management of these patients. The current study was therefore undertaken to assess the risk of development of another primary malignant tumor in adult patients with STS.

MATERIALS AND METHODS

PATIENTS

The records of 500 consecutive adult STS patients diagnosed and treated between February 1962 and August 2003 were

For reprints and all correspondence: Ukihide Tateishi, Division of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, 104-0045 Tokyo, Japan. E-mail: utateish@ncc.go.jp

retrieved from the pathology files of our institution. This study was approved by the local Ethics Committees after confirmation of informed consent by the patients to a review of their records and images. The enrollment criteria consisted of (i) adult STS patients whose pathological specimens and medical charts were available for review; and (ii) patients who were not lost to follow-up. The exclusion criteria consisted of (i) subjects whose pathological specimens and medical charts were insufficient for review; and (ii) subjects whose pathological subtypes were considered to be rare in the clinical setting. Thus, 94 patients (19%) whose tumors comprised epithelioid sarcoma ($n = 25$), alveolar soft part sarcoma ($n = 20$), clear cell sarcoma ($n = 16$), extraskeletal myxoid chondrosarcoma ($n = 20$) or extraskeletal osteosarcoma ($n = 13$) were excluded from the analysis, and the 406 patients with common STSs were included in the analysis. The patients consisted of 223 men and 183 women, and they ranged in age from 16 to 87 years (median age: 53 years). During the period 1962–2003, the concept of MFH or myxofibrosarcoma changed. Twenty-three myxofibrosarcomas (34%) which were previously diagnosed as myxoid variant of MFH or solely fibrosarcoma were reclassified by the review of pathological examinations. Autopsy was performed in 16 cases (4%) and their pathological specimens were also available for review.

In the patients who developed multiple primary malignancies, we investigated: age at diagnosis, gender, family history, anatomic site, tumor size, depth, surgical margin, histological type, MIB-1 score, grade, whether chemotherapy has been performed, whether radiation therapy has been performed and the outcome. If the patient had died, the date and the cause of death were also noted.

Patients were followed-up with regard to survival until August 31, 2004, at which time 250 patients were alive with no evidence of disease, 26 patients were alive with disease and 130 patients had died of their disease. The malignancy-free survival period (MFSP) was measured from the date of diagnosis of STS to the date of the first observations of multiple malignancies. If the detection of malignancy other than STS preceded the date of diagnosis of the STS, the MFSP was recorded as 0. If a patient was alive without developing any multiple malignancies at the last visit, the data on MFSP were censored as of the date when the survival was confirmed. If a patient died without detection of other primary malignancies, the MFSP was censored at the date of death. If other primary malignancy was found at autopsy, the date of death was treated as an event.

Histological slides of the primary tumors of all patients were reviewed for diagnosis by two experts. Whenever necessary, immunohistochemistry was used to confirm the diagnosis or tumor type according to the WHO classification (12). MIB-1 immunostaining was performed to grade all tumors. An MIB-1 score of 1 was assigned to lesions with an MIB-1 labeling index (LI) of 0–9%, an MIB-1 score of 2 was given to lesions with an MIB-1 LI of 10–29%, and an MIB-1 score of 3 was given to lesions with an MIB-1 LI $\geq 30\%$. There were tumors with an MIB-1 score of 1 ($n = 140$; 35%), 2 ($n = 62$; 15%) and

3 ($n = 204$; 50%). The histological grade is a three-grade system obtained by adding the scores for tumor differentiation, tumor necrosis and MIB-1 score, each of which was given a score of 0–3 (13). By using the grading system, tumors corresponded to grade 1 ($n = 128$; 32%), grade 2 ($n = 107$; 26%) and grade 3 ($n = 171$; 42%), respectively. Tumor depth was measured relative to muscular fascia that had been invaded and was characterized as superficial or deep. The vast majority of lesions ($n = 322$; 79%) were deep seated, and 94 tumors were superficial.

STATISTICAL ANALYSIS

Univariate analysis of the cumulative incidence of multiple malignancies was performed by comparing Kaplan–Meier curves and log-rank tests from each histological type. The hazard ratio (HR) of each variable was estimated by using a Cox proportional hazards model in the univariate and multivariate analyses. The following factors are considered as potential confounding factors for the incidence of multiple malignancies: age at presentation, gender, family history of malignant neoplasm, anatomic site, tumor size, depth, surgical margin, histological type, MIB-1 score (1, 2 or 3) and grade (1, 2 or 3). Variable selection by the backward elimination ($\alpha = 0.2$) procedure was performed in the multivariate analyses. All analyses were performed with SAS Software (version 6.12; SAS Institute, Cary, NC).

RESULTS

Tumors had a diameter >5 cm in 302 patients (74%). Most tumors were located in the extremities ($n = 244$; 60%) compared with the trunk ($n = 96$; 24%) and other sites ($n = 66$; 16%). The histological types consisted of liposarcoma ($n = 159$; 39%), myxofibrosarcoma ($n = 67$; 17%), pleomorphic MFH ($n = 53$; 13%), synovial sarcoma ($n = 50$; 12%), leiomyosarcoma ($n = 32$; 8%), malignant peripheral nerve sheath tumor (MPNST; $n = 25$; 6%) and fibrosarcoma ($n = 20$; 4%). Of these 406 tumors, 371 tumors (91%) did not develop multiple malignancies (Table 1).

A total of 35 patients (9%) with STS were documented in the study population, among whom the STS was preceded by ($n = 15$) and followed by ($n = 20$) malignancies other than STS. The median age at the time of diagnosis of the first tumors was 63 years (range 39–79 years). The SPTs were diagnosed a median of 64 months after the diagnosis of the first tumor. A third primary tumor (TPT) was found in eight patients, a median of 127 months after the first tumor. One patient was found to have a fourth primary tumor 331 months after the first tumor. The overall 5- and 10-year estimated cumulative incidence of multiple primary malignancy was 7.6% [95% confidence interval (CI) 4.7–10.4] and 12.3% (95% CI 7.4–18.0), respectively.

Information related to the patients is listed in Table 2. The most frequent histological types of STS were myxofibrosarcoma ($n = 13$; 19.4%) and pleomorphic MFH ($n = 6$; 11.3%).

Table 1. Demographics of patients without multiple malignancies

Variables	LS	MFS	PMFH	SS	LMS	MPNST	FS	Total
n	148	54	47	50	30	24	18	371
Mean age (years)	51.6	60.5	57.9	32.9	55.3	50.0	42.4	50.9
SD	12.8	13.1	14.3	15.4	13.8	15.5	21.5	16.3
Range	18–87	29–87	26–86	18–72	30–83	28–74	18–87	18–87
Gender								
Male	89	27	31	22	11	9	12	201
Female	59	27	16	28	19	15	6	170
Distribution								
Extremities	91 (62)	37 (69)	31 (66)	36 (72)	6 (20)	13 (54)	12 (67)	226 (60)
Trunk	21 (14)	16 (30)	15 (32)	11 (22)	9 (30)	10 (42)	5 (28)	87 (23)
Others	36 (24)	1 (2)	1 (2)	3 (6)	15 (50)	1 (4)	1 (6)	58 (15)
MIB-1 score								
1	99 (67)	10 (19)	2 (4)	5 (10)	2 (7)	5 (21)	7 (39)	130 (34)
2	17 (12)	14 (26)	3 (6)	12 (24)	3 (10)	1 (4)	6 (33)	56 (15)
3	32 (22)	30 (56)	42 (89)	33 (66)	25 (83)	18 (75)	5 (29)	185 (49)
Grade								
1	94 (64)	9 (17)	2 (4)	0	2 (7)	4 (17)	8 (44)	119 (31)
2	22 (15)	34 (63)	8 (17)	14 (28)	7 (23)	2 (8)	7 (39)	94 (25)
3	32 (22)	11 (20)	37 (79)	36 (72)	21 (70)	18 (75)	3 (17)	158 (42)
Depth								
Superficial	19 (13)	16 (30)	14 (30)	7 (14)	6 (20)	4 (17)	5 (28)	71 (19)
Deep	129 (87)	38 (70)	33 (70)	43 (86)	24 (80)	20 (83)	13 (72)	300 (79)
Size (cm)								
0–5	10 (7)	20 (37)	15 (32)	24 (48)	8 (27)	7 (29)	11 (61)	95 (26)
5–10	59 (40)	25 (46)	17 (36)	18 (36)	13 (43)	13 (54)	5 (28)	150 (40)
>10	79 (53)	9 (17)	15 (32)	8 (16)	9 (30)	4 (17)	2 (11)	126 (33)
Margin								
Adequate	105 (71)	46 (85)	44 (94)	45 (90)	26 (87)	17 (71)	15 (83)	298 (79)
Inadequate	43 (29)	8 (15)	3 (6)	5 (10)	4 (13)	7 (29)	3 (17)	73 (19)
Chemotherapy	28 (19)	13 (24)	24 (51)	31 (62)	12 (40)	13 (54)	6 (33)	127 (34)
Radiation therapy	36 (24)	19 (35)	14 (30)	11 (22)	10 (33)	10 (42)	4 (22)	104 (27)
Family history of cancer	21 (49)	4 (9)	6 (14)	2 (5)	2 (5)	6 (14)	2 (5)	43 (12)
Survival rate (%)								
5 year	86.7	89.3	51.6	61.8	27.5	45.2	66.2	71.7
10 year	78.5	69.6	41.4	48.4	27.5	24.1	48.4	57.7

The numbers in parentheses are percentages.
LS, liposarcoma; MFS, myxofibrosarcoma; PMFH, pleomorphic malignant histiocytoma; SS, synovial sarcoma; LMS, leiomyosarcoma; MPNST, malignant peripheral nerve sheath tumor; FS, fibrosarcoma.

Less common histological types consisted of fibrosarcoma ($n = 2$; 10%), liposarcoma ($n = 11$; 6.9%), leiomyosarcoma ($n = 2$; 6.3%) and MPNST ($n = 1$; 4%).
The risk of multiple malignancies differed significantly according to the histological type of the STS (log rank test: $P = 0.0055$). None of the patients with synovial sarcoma had multiple malignancies. The multivariate analysis adjusted for potential confounding variables showed a higher risk of

multiple malignancy in patients with myxofibrosarcoma (Table 3). When patients with pleomorphic MFH and myxofibrosarcoma were combined into the same histological category, the risk of multiple malignancies was 2.13 (95% CI 1.00–4.55, $P = 0.0496$). However, no significant association was found between risk of multiple malignancies and survival rate, or familiar history of malignant neoplasm in pleomorphic MFH and myxofibrosarcoma.

Table 2. Demographics of patients with multiple malignancies

Variables	MFS	PMFH	Other tumors	Total
<i>n</i>	13 (37)	6 (17)	16 (46)	35
Mean age (years)	63.8	66.5	58.8	62.0
SD	11.4	13.1	10.9	11.5
Range	45–79	47–76	39–79	39–79
Gender				
Male	10	5	7	22
Female	3	1	9	13
Distribution				
Extremities	10 (77)	2 (33)	6 (38)	18 (51)
Trunk	3 (23)	4 (66)	2 (13)	9 (26)
Others	0	0	8 (50)	8 (23)
MIB-1 score				
1	3 (23)	0	7 (44)	10 (29)
2	3 (23)	0	3 (19)	6 (17)
3	7 (54)	6 (100)	6 (38)	19 (54)
Grade				
1	3 (23)	0	6 (38)	9 (26)
2	8 (62)	1 (17)	4 (26)	13 (37)
3	2 (15)	5 (83)	6 (38)	13 (37)
Depth				
Superficial	9 (69)	4 (66)	0	13 (37)
Deep	4 (30)	2 (33)	16 (100)	22 (63)
Size (cm)				
0–5	5 (38)	1 (17)	3 (19)	9 (26)
5–10	7 (54)	5 (83)	4 (26)	16 (46)
10+	1 (8)	0	9 (69)	10 (29)
Margin				
Adequate	11 (85)	6 (100)	11 (69)	28 (80)
Inadequate	2 (15)	0	5 (31)	7 (20)
Survival rate (%)				
5 year	84.6	50.0	66.1	70.0
10 year	70.5	16.7	27.3	43.1

The numbers in parentheses are percentages.
MFS, myxofibrosarcoma; PMFH, pleomorphic malignant fibrous histiocytoma.

Twelve patients (37.1%) had a family history of cancer. One patient had familial adenomatous polyposis (FAP) with a germline mutation in the APC gene. Two patients with a second or third primary STS had previously received systemic chemotherapy and radiation therapy. Patients with a second or third primary cancer whose STS preceded it had previously received chemotherapy (*n* = 3) and radiation therapy (*n* = 4). Only one patient had a third primary cancer within the radiation field.

Age at the time of diagnosis was associated with increased risk of multiple malignancies in the unadjusted analysis (HR = 1.52, 95% CI 1.17–1.97, *P* = 0.0016), but

Table 3. Hazard risk of multiple malignancies adjusted for potential confounding variables

Variables	HR	95% CI	<i>P</i> -value
Age	1.51	1.17–1.96	0.0019
Tumor size	1.03	0.99–1.07	0.18
MFS	2.34	1.01–5.41	0.048
PMFH	1.85	0.69–4.97	0.22
Other tumors*	1	–	–

*Adjusted hazard risk (HR) referenced to other tumors is presented.
MFS, myxofibrosarcoma; PMFH, pleomorphic malignant fibrous histiocytoma.

no significant association was found with gender, family history of cancer, MIB-1 score, grade, tumor size, depth or margin. Furthermore, no interaction was evidenced between the risk of multiple malignancies and having received chemotherapy or radiation therapy.

Myxofibrosarcoma developed as the first tumor in three patients, the second tumor in seven, the third tumor in two, and the fourth tumor in one (Table 4). The MFSP between the diagnosis of the first and second malignancies ranged from 4 to 275 months (median: 69.0 months). The TPTs were detected within 142 months after the diagnosis of the first tumor. One myxofibrosarcoma of the thigh developed after radiation therapy for a second primary esophageal carcinoma. The fourth primary tumor developed in a patient who had undergone surgical resection three times for carcinomas of the colon and cecum. The patient developed a myxofibrosarcoma of the thigh that was treated by surgery and chemotherapy 120 months after the diagnosis of the SPT. The 5- and 10-year estimated cumulative incidence of multiple malignancies in patients with myxofibrosarcoma were both 16.9% (95% CI 7.8–26.1; Fig. 1). The overall survival time of the 13 patients in the group after the diagnosis of the first tumor ranged from 10 to 408 months (median: 148.0 months). The 5-year survival rate of the group was similar to that of the patients without multiple malignancies (84.6 versus 89.3%, *P* = 0.81).

Pleomorphic MFH occurred as the first tumor in five patients (Table 5), and in one patient it was followed by esophageal carcinoma. The MFSP between the diagnosis of the first and second malignancies varied from 17 to 94 months (median: 74.0 months). The 5-year estimated cumulative incidence of multiple malignancies in patients with pleomorphic MFH was 10.2% (95% CI 0.0–20.6; Fig. 1). The overall survival time of the six patients in this group ranged from 48 to 155 months (median: 113.0 months), and the 5-year survival rate was not significantly different from that of pleomorphic MFH patients without multiple malignancies (50.0 versus 51.6%, *P* = 0.32). One patient died of the first tumor after developing a metastasis, and the other five patients died of the SPT.

Nineteen multiple malignancies were associated with four types of adult STSs: liposarcomas in 11 patients, fibrosarcomas in two, leiomyosarcomas in two and MPNST in one (Table 6). The MFSP between the diagnosis of the primary malignancy

Table 4. Myxofibrosarcoma with multiple malignancies (n = 13)

Patient	Age (years)	Gender	FT Site	CT	RT	MFSP SPT	Site	CT	RT	MFSP from SPT	TPT	Site	CT	RT	MFSP from TPT	FPT	Site	CT	RT	Prognosis	OS
1	55	Male	MFS	Thigh	-	-	4	Ad	Stomach	-	-	-	-	-	-	-	-	-	-	NED	10
2	68	Male	MFS	Buttock	-	-	8	Sq	Pharynx	-	50 Gy	-	-	-	-	-	-	-	-	DOD	246
3	48	Female	MFS	Leg	-	-	130	Ad	Ovary	CDDP + ADR + CPA	-	-	-	-	-	-	-	-	-	DOD	177
4	69	Male	Ad	Stomach	-	-	38	MFS	Thigh	CDDP + Taxel	-	-	-	-	-	-	-	-	-	DOD	101
5	66	Male	TCC	Bladder	-	-	11	MFS	Chest wall	-	5	TCC	Bladder	ADR	-	-	-	-	-	NED	156
6	69	Male	Sq	tongue	CDDP	50 Gy	84	MFS	Leg	-	7	Sq	Gingiva	-	-	-	-	-	-	NED	91
7	70	Male	Ad	Rectum	-	-	19	MFS	Arm	-	42 Gy	-	-	-	-	-	-	-	-	DOD	34
8	74	Male	Ad	Prostate	-	-	4	MFS	Arm	-	-	-	-	-	-	-	-	-	-	NED	24
9	48	Female	Ad	Breast	-	-	85	MFS	Arm	-	-	-	-	-	-	-	-	-	-	NED	143
10	79	Female	RCC	Kidney	-	-	139	MFS	Arm	-	-	-	-	-	-	-	-	-	-	NED	148
11	77	Male	Ad	Colon*	-	-	275	Ad	Stomach	-	105	MFS	Leg	-	-	-	-	-	-	NED	381
12	45	Male	Ad	Stomach	-	-	216	Sq	Esophagus	-	60 Gy	84	MFS	Thigh	-	-	-	-	-	NED	408
13	62	Male	Ad	Colon	-	-	69	Ad	Cecum	-	142	Ad	Colon	-	-	120	MFS	Thigh	CDDP	NED	331

FT, first tumor; CT, chemotherapy; RT, radiotherapy; MFSP, malignancy-free survival period (months); SPT, second primary tumor; TPT, third primary tumor; FPT, fourth primary tumor; DOD, died of disease; NED, no evidence of disease; OS, overall survival (months); MFS, myxofibrosarcoma; Ad, adenocarcinoma; Sq, squamous cell carcinoma; TCC, transitional cell carcinoma; RCC, renal cell carcinoma; CDDP, cisplatin; ADR, adriamycin; CPA, cyclophosphamide; 5FU, 5-fluorouracil.
*Synchronous tumor.

and the second malignancy ranged from 1 to 141 months (median: 60.0 months). The 5- and 10-year estimated cumulative incidence of multiple malignancies in this group was 5.1% (95% CI 2.2–8.0) and 9.7% (95% CI 3.8–15.7%; Fig. 1), respectively. The overall survival time of the 16 patients from the time of diagnosis of the first tumor ranged from 6 to 223 months (median: 96.5 months). No significant difference in 5-year survival rate was found between the patients with and without multiple malignancies (66.1 versus 71.6%, $P = 0.80$).

DISCUSSION

The objective of this study was to review the incidence of multiple malignancy in adult STS patients. The results of the analysis showed that 9% of the patients had multiple malignancies. The 5- and 10-year estimated cumulative incidence of multiple malignancy was 7.6% (95% CI 4.7–10.4) and 12.3%




Figure 1. Cumulative incidence of multiple malignancies in STS. MFS, myxofibrosarcoma; PMFH, pleomorphic malignant fibrous histiocytoma. A statistically significant difference is found between the three groups (log rank $P = 0.002$).

Table 5. Pleomorphic MFH with multiple malignancies ($n = 6$)

Patient	Age (years)	Gender	FT	Site	CT	RT	MFSP	SPT	Site	CT	RT	MFSP from SPT	TPT	Site	CT	RT	Prognosis	OS
1	76	Male	PMFH	Shoulder	—	32.5 Gy	64	Ad	Bile duct	MMC	—	—	—	—	—	—	DOD	78
2	76	Male	PMFH	Thigh	—	—	84	Ad	Lung	—	—	—	—	—	—	—	DOD	155
3	53	Male	PMFH	Elbow	VCR	—	6	Sq	Tongue	—	—	—	—	—	—	—	DOD	106
ADR																		
4	47	Male	PMFH	Buttock	—	—	31	Ad	Colon	—	—	—	—	—	—	—	DOD	48
5	76	Male	PMFH	Back	—	50 Gy	121	Ad	Stomach	—	50 Gy	—	—	—	—	—	DOD	138
6	71	Male	Sq	Esophagus	—	—	94	PMFH	Back	—	—	7	Ad	Stomach	—	—	DOD	120

FT, first tumor; CT, chemotherapy; RT, radiotherapy; MFSP, malignancy-free survival period (months); SPT, second primary tumor; TPT, third primary tumor; DOD, died of disease; NED, no evidence of disease; OS, overall survival (months); PMFH, pleomorphic malignant fibrous histiocytoma; Sq, squamous cell carcinoma; Ad, adenocarcinoma; VCR, vincristine; ADR, adriamycin; MMC, mitomycin C.

(95% CI 7.4–18.0), respectively. In addition, the risk of multiple malignancy appeared to be impacted by age at the time of diagnosis of the first tumor and by the histological type of myxofibrosarcoma.

The results of this analysis add to the evidence of an association between STS and the risk of multiple malignancy. The results are consistent with the findings in the cohort study Merimsky et al. that assessed the risk of multiple malignancies associated with STS (11). In their study, 28 of 375 adult patients (7.5%) with STS were found to have developed another primary malignant neoplasm either before or after the diagnosis of STS, a significantly higher rate than reported for the occurrence of STS in the general cancer patient population (1.0%). In addition, they also observed an association between primary MFH and the occurrence of renal cell carcinoma. However, Merimsky et al. did not evaluate risk according to histological types of STS, and they included several patients with bone sarcoma in their analysis. Thus, our study expanded on the findings of Merimsky et al. by assessing the impact of histological type.

Previous studies in patients with STS have found frequencies of an SPT ranging from 1.2 to 6.0% (14,15). In contrast, one study that investigated the risk of developing SPT in patients with non-Hodgkin lymphoma yielded a frequency of 15.4% (16). However, the populations in these studies were mainly children or adolescents. In our study, the rate of association of an SPT or TPT with STS was 9.0%, suggesting that the frequency of multiple malignancies is similar in the different age populations. Age at the time of diagnosis was strongly associated with increased risk of multiple malignancies in adult patients with STS.

The results of our study showed that the risk of multiple malignancies was similar when the analysis was conducted separately for patients with pleomorphic MFH and myxofibrosarcoma, the most common types of STS. Multiple malignancies were detected in six patients with pleomorphic MFH, and in five patients where the pleomorphic MFH was preceded by another malignant tumor. Similarly, the other malignancy was detected first in three of the 13 patients (23%) with myxofibrosarcoma and subsequently in the other